Quanterix Corporation (NASDAQ:QTRX) Receives Consensus Rating of “Hold” from Analysts

Quanterix Corporation (NASDAQ:QTRX) has earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.3333.

QTRX has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a report on Wednesday, October 8th. Canaccord Genuity Group reissued a “hold” rating and issued a $5.00 price objective (down previously from $12.00) on shares of Quanterix in a research report on Monday, August 11th.

Hedge Funds Weigh In On Quanterix

A number of large investors have recently modified their holdings of the business. State of Wyoming acquired a new stake in shares of Quanterix in the first quarter valued at about $47,000. R Squared Ltd acquired a new position in Quanterix during the third quarter valued at approximately $64,000. Quantbot Technologies LP grew its stake in Quanterix by 245.9% in the first quarter. Quantbot Technologies LP now owns 11,272 shares of the company’s stock valued at $73,000 after purchasing an additional 8,013 shares in the last quarter. HUB Investment Partners LLC bought a new position in Quanterix in the second quarter valued at approximately $81,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Quanterix during the 2nd quarter worth approximately $96,000. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Stock Performance

Shares of Quanterix stock opened at $5.74 on Monday. Quanterix has a 52 week low of $4.05 and a 52 week high of $13.01. The firm has a fifty day moving average of $5.41 and a two-hundred day moving average of $5.46. The stock has a market capitalization of $268.12 million, a price-to-earnings ratio of -2.46 and a beta of 1.12.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Monday, November 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.13). The company had revenue of $40.23 million for the quarter, compared to analyst estimates of $37.85 million. Quanterix had a negative return on equity of 21.34% and a negative net margin of 73.47%. Quanterix has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Quanterix will post -0.98 EPS for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.